Muna Launches On 'Rising Tide' Of Alzheimer's

Raises $73m In Series A Financing

Backed by investors such as Sofinnova, Polaris and Sanofi Ventures, Muna has assembled a strong team dedicated to developing small molecules to repair neuronal dysfunction and resolve neuroinflammation.

Memory loss due to dementia. Senior woman losing parts of head feeling confused as symbol of decreased mind function. - Image
• Source: Archive

Against the background of the upsurge in interest in Alzheimer's disease driven by the recent controversial US approval of Biogen's Aduhelm, Muna Therapeutics has launched with an impressive $73m series A financing supported by a global syndicate of big name investors who are backing the Danish biotech's approach to slowing or stopping neurodegenerative diseases.

Muna, which means 'to remember' in old Norse, was founded in 2020 by Simon Glerup and his team from Aarhus...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.